Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ET7S | ISIN: CA47817E1034 | Ticker-Symbol: JNJ0
Frankfurt
23.07.25 | 08:09
13,300 Euro
0,00 % 0,000
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
JOHNSON & JOHNSON CDR Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON CDR 5-Tage-Chart

Aktuelle News zur JOHNSON & JOHNSON CDR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJanssen-Cilag: European Commission Approves New Indication For Daratumumab SC220NEW BRUNSWICK (dpa-AFX) - Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved a new indication for DARZALEX or daratumumab subcutaneous...
► Artikel lesen
MiErste Group upgrades Johnson & Johnson stock rating to Buy from Hold5
MiJohnson & Johnson erhält EU-Zulassung für Darzalex zur Behandlung des schwelenden Myeloms/n5
MiJohnson & Johnson's Darzalex gets EU approval for smouldering myeloma4
MiJohnson & Johnson, Pacira partner to expand osteoarthritis treatment options3
MiPacira, J&J MedTech Partner To Expand Reach Of ZILRETTA For Osteoarthritis Knee Pain4
DiJohnson & Johnson MedTech, Pacira BioSciences Partner To Promote ZILRETTA For Knee OA Pain323NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson MedTech - the medical technology business segment of Johnson & Johnson (JNJ) has entered a strategic co-promotion agreement with Pacira BioSciences...
► Artikel lesen
DiJNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra8
JOHNSON & JOHNSON CDR Aktie jetzt für 0€ handeln
DiJ&J Files for FDA Approval of Oral Psoriasis Drug Icotrokinra4
DiPacira signs partnership with JNJ to expand Zilretta6
DiJ&J seeks FDA approval for icotrokinra to treat psoriasis5
DiJohnson & Johnson (JNJ)'s Pasritamig Shows Breakthrough Promise in Prostate Cancer2
MoAstraZeneca, facing lung cancer challenge from J&J, touts life extension benefit for Tagrisso combo4
MoJohnson & Johnson seeks icotrokinra FDA approval8
MoJohnson & Johnson Submits NDA For Icotrokinra In Plaque Psoriasis328NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Monday said it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra for the treatment of...
► Artikel lesen
MoShould J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?4
MoJohnson & Johnson seeks FDA approval for new psoriasis drug5
MoJohnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis103Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that...
► Artikel lesen
SoNotable healthcare headlines for the week: Trump's tariff threats, J&J, Abbott Laboratories and Sarepta in focus28
SaInsider trades: J&J, Morgan Stanley among notable names this week7
Weiter >>
740 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1